Foundayo vs Wegovy Pill: Oral Weight-Loss Tablets Compared

If you've been holding off on starting a medicated weight loss journey because the thought of injecting puts you off, then this article is for you.

The Wegovy pill (oral semaglutide) was approved by the MHRA on the 11th of June 2026 and now there’s talk of another new weight loss pill by Eli Lilly called Foundayo (orforglipron).

Both are once-daily tablets from the same broad class of medicine and both have delivered double-digit average weight loss in large clinical trials. But they differ in their chemistry, in how you take them and - the part that matters most if you're in the UK - in whether you can actually get hold of one. This guide sets the two side by side so you can see how they compare.

The short answer for UK patients today: the Wegovy pill is licensed by the MHRA and available on private prescription; Foundayo (orforglipron) is not yet licensed in the UK and cannot be prescribed or supplied here. That single fact decides the choice for most people right now - the rest of this article explains why, and how the two would compare once both are available.

At a glance: Foundayo vs Wegovy pill

Trial weight-loss figures come from separate studies with different participants, doses and durations, so they are a general guide, not a head-to-head result. See Effectiveness below.

What each medicine is and how they work

The Wegovy pill (oral semaglutide)

The Wegovy pill is a tablet form of semaglutide, made by Novo Nordisk - the same active ingredient as the Wegovy injection. On 11 June 2026 the MHRA licensed it for weight management, making it the first weight-loss tablet of any kind approved in the UK.[1]

It is available here on private prescription for eligible adults and is not currently on the NHS. For full dosing, eligibility and pricing, see our Wegovy pill page.

• Read our full guide on semaglutide

The Foundayo pill (orforglipron)

Foundayo is the US brand name for orforglipron, a tablet developed by Eli Lilly. Its key difference from semaglutide is chemical: semaglutide is a peptide, whereas orforglipron is a small, non-peptide molecule, which is why it survives digestion without the strict food-and-water timing rules that oral semaglutide needs.[3][4]

The US FDA approved it on 1 April 2026, but the MHRA has not licensed it, so it cannot lawfully be prescribed or supplied in the UK - including on a private prescription.[3]

A NICE appraisal is expected on 18 November 2026, though a UK licence would have to come first.[6] Our Foundayo (orforglipron) page tracks the UK position.

• Read our full guide on orforglipron

How they work

Both belong to the GLP-1 receptor agonist class and therefore, both drugs work in the same way. After you eat, your gut naturally releases a hormone that tells your brain you're full. These medicines copy that hormone, so your body gets that "I've had enough" signal quicker and it stays for longer.

In practice that means three things: you feel less hungry, food stays in your stomach longer (so you stay full after smaller meals), and sticking to a lower-calorie diet becomes easier because you're not fighting constant hunger.

Wegovy vs Foundayo effectiveness: what the trials show

In the OASIS 4 trial, adults taking the 25 mg Wegovy tablet lost an average of around 13.6% of their body weight over 64 weeks.[2]

In the separate ATTAIN-1 trial, adults on the highest 36 mg dose of orforglipron lost an average of about 11.2% over 72 weeks, with roughly six in ten of those on the top dose losing at least 10% of their body weight.[5]

Taken at face value the Wegovy pill produced a slightly higher average, but the two were never compared head-to-head. They were studied in different trials with different participants, doses, durations and statistical methods, so the percentages are not directly interchangeable.

The practical takeaway is that both deliver meaningful, double-digit average weight loss for a tablet - and that a prescriber, not a league table, is the right way to judge which is appropriate for you.

How do Foundayo and Wegovy work differently?

Foundayo and Wegovy genuinely differ in how the two are consumed.

The Wegovy pill has strict administration rules. You must swallow it whole on an empty stomach, having fasted for at least eight hours, with no more than a small sip of water. You then wait 30 minutes before eating, drinking, or taking any other medication. These steps aren't just guidance; they're essential for the tablet to be absorbed properly.[1]

Orforglipron has no such requirements. Because it's a small molecule, it can be taken at any time of day, with or without food or water.[3][4]

What they have in common is the dosing approach: both start at a low dose and step up gradually to minimise side effects. The full titration schedules are on each product page.

Side effects and safety

Because they share a drug class, the two have a broadly similar safety profile. The most common side effects are gastrointestinal - nausea, vomiting, diarrhoea and constipation - which tend to be mild to moderate and are most likely when starting or increasing the dose.[2][5]

Rarer but more serious risks associated with the class include pancreatitis and gallbladder problems. In January 2026 the MHRA strengthened its warnings on acute pancreatitis for GLP-1 medicines, advising anyone with severe, persistent stomach pain that may spread to the back - sometimes with nausea and vomiting - to seek urgent medical attention.[7]

In the United States, orforglipron also carries a boxed warning about a possible risk of thyroid C-cell tumours, a precaution applied across parts of this drug class.[4]

Neither medicine is suitable in pregnancy or breastfeeding, neither is for children, and neither is right for everyone - which is exactly why a prescriber assessment is required.

Any suspected side effect from any medicine can be reported through the MHRA Yellow Card scheme.[8]

The decisive difference: UK availability

On availability, the two could not be further apart. The Wegovy pill is MHRA-licensed and can be prescribed privately in the UK now. Foundayo is not licensed here, so no UK pharmacy - including ours - can supply it, whatever route you go through; a private prescription still requires a UK licence.[1][3]

If you see a website offering orforglipron or Foundayo to UK customers today, treat it as a warning sign, as buying prescription medicines from unregulated sources carries a real risk of counterfeit or contaminated product. We will add orforglipron to our range only once it holds a UK licence.

How to choose between Wegovy and Foundayo

For anyone in the UK weighing up an oral weight-loss medicine today, the honest answer is that only one of these two is a real option: the Wegovy pill. Foundayo may follow if and when it is licensed here, but it should not be sought in the meantime.

Either way, these medicines work best as one part of a broader approach that includes diet, physical activity and ongoing support, and both are prescription-only for good reason.

If you think a weight-management medicine might be right for you, the next step is an assessment with a clinician. You can start with your GP or pharmacist or begin an online consultation through our weight-loss service, where a prescriber can talk you through the options that are genuinely available and suitable for you.

• Learn more about our weight loss service

Foundayo vs Wegovy pill FAQs

Is orforglipron better than Wegovy?

No study has directly compared the two, so nobody can reliably claim one is "better."

Each was tested in its own separate trial. In those, the 25 mg Wegovy tablet gave slightly more average weight loss (around 13.6% over 64 weeks) than the 36 mg dose of orforglipron (around 11.2% over 72 weeks). But because these came from different trials, the numbers can't be compared like-for-like.[2][5]

The clearest real-world difference is convenience. Orforglipron has no rules about food or water timing, while the Wegovy pill has to be taken after an 8-hour fast with a 30-minute wait afterwards.[1][3]

For anyone in the UK, though, the deciding factor is simpler: only the Wegovy pill is actually licensed and available.

Can I buy Foundayo in the UK?

No. Orforglipron holds no UK marketing authorisation, so it cannot legally be prescribed, supplied or sold here - not even on a private prescription.[3][6] Once it is licensed, it would become available on private prescription from registered pharmacies.

Are they both once-daily tablets?

Yes. Both are taken once a day. The difference is timing: the Wegovy pill has strict fasting rules; Foundayo can be taken at any time.[1][3]

References

[1] Medicines and Healthcare products Regulatory Agency. First GLP-1 tablet for weight loss approved in the UK. GOV.UK, 11 June 2026. https://www.gov.uk/government/news/first-glp-1-tablet-for-weight-loss-approved-in-the-uk

[2] Garvey WT, et al. Oral Semaglutide at a Dose of 25 mg in Adults with Overweight or Obesity (OASIS 4). N Engl J Med. 2025;393(11):1077–1087. doi:10.1056/NEJMoa2500969. https://www.nejm.org/doi/full/10.1056/NEJMoa2500969

[3] Eli Lilly and Company. FDA approves Lilly's Foundayo (orforglipron), the only GLP-1 pill for weight loss that can be taken any time of day without food or water restrictions. 1 April 2026. https://investor.lilly.com/news-releases/news-release-details/fda-approves-lillys-foundayotm-orforglipron-only-glp-1-pill

[4] Eli Lilly and Company. FOUNDAYO (orforglipron) tablets, for oral use - US Prescribing Information. US Food and Drug Administration, 2026. https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/220934Orig1s000lbl.pdf

[5] Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment (ATTAIN-1). N Engl J Med. 16 September 2025. doi:10.1056/NEJMoa2511774. https://www.nejm.org/doi/full/10.1056/NEJMoa2511774

[6] National Institute for Health and Care Excellence. Orforglipron for managing overweight and obesity [ID6516]. In development; publication expected 18 November 2026. https://www.nice.org.uk/guidance/indevelopment/gid-ta11650

[7] Medicines and Healthcare products Regulatory Agency. GLP-1 receptor agonists and dual GLP-1/GIP receptor agonists: strengthened warnings on acute pancreatitis, including necrotising and fatal cases. Drug Safety Update, 29 January 2026. https://www.gov.uk/drug-safety-update/glp-1-receptor-agonists-and-dual-glp-1-slash-gip-receptor-agonists-strengthened-warnings-on-acute-pancreatitis-including-necrotising-and-fatal-cases

[8] Medicines and Healthcare products Regulatory Agency. Yellow Card scheme. https://yellowcard.mhra.gov.uk/